Latest filing published 20 Nov 2018 for CytoDyn Inc., €4.2M.
Insider track record
Richard Pestell MD: trading record in brief
Richard Pestell MD discloses dealings in CytoDyn Inc. to SEC (Form 4). Altogether 2 filings, all relating to 16 November 2018.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
The latest filing, published on 20 November 2018, reports a share grant of €4.2M in CytoDyn Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Richard Pestell MD
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 8,342,000 shares@ US$0.569639.5% of flowCommon StockSEC:0000899243-18-029500:0
- 12,782,440 shares@ US$0.569660.5% of flowCommon StockSEC:0000899243-18-029500:1
2 of 2 declarations